Zytiga Tablet
Product Images NDC 57894-150

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Zytiga (NDC 57894-150). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Janssen Biotech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Zytiga 01)

FDA Label Image

Figure 1 (Zytiga 02)

FDA Label Image

Figure 2 (Zytiga 03)

Figure 2 (Zytiga 03)
This appears to be a table showing the number of subjects without death over time, separated by months from randomization, for two different treatments (Zytign and Placebo). The numbers shown represent the number of subjects without death at each time point.*
FDA Label Image

Figure 3 (Zytiga 04)

FDA Label Image

Principal Display Panel (250 mg Bottle Label)

FDA Label Image

Principal Display Panel (250 mg Tablet Bottle Label 184-12)

Principal Display Panel (250 mg Tablet Bottle Label 184-12)
Zytiga is a prescription medicine that contains 250 mg of abiraterone acetate per tablet. It is recommended to store the tablets between 20°C to 25°C (68°F to 77°F) with permitted excursions of 15°C to 30°C (59°F to 86°F). The tablets should be swallowed whole and should not be crushed or chewed. Women who are pregnant should not handle Zytiga without gloves. The medicine should be kept out of reach of children. It is produced in Belgium and distributed by Janssen Biotech, with the details of manufacturing for Horsham, PA19044. Dosage information and administration can be found in the prescribing information. Other details such as its lot number, expiration date, and GTIN are also available.*
FDA Label Image

Principal Display Panel (500 mg Bottle Label)

Principal Display Panel (500 mg Bottle Label)
Zytiga is a medication used to treat prostate cancer. The tablets are film-coated and contain 500mg of abiraterone acetate. The recommended dosage is stated in the prescribing information, and the tablets should not be crushed or chewed. The product should be stored at room temperature and kept out of reach of children. The medication is a product of Belgium and manufactured for Janssen Biotech in Horsham, PA. The text also includes several identification codes.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.